Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

A. Jänne, Pasi; S. Boss, David; Ross Camidge, D.; D. Britten, Carolyn; A. Engelman, Jeffrey; B. Garon, Edward; Guo, Feng; Wong, Steven; Liang, Jane; Letrent, Stephen; Millham, Robert; Taylor, Ian; Gail Eckhardt, S.; H.M. Schellens, Jan

doi:10.1158/1078-0432.ccr-10-1220

Public

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Shared by NobleBlocks on Mar 1, 2011 • 12:00 AM UTC

Authors:

Pasi A. Jänne

David S. Boss

D. Ross Camidge

Abstract

Abstract Purpose: PF299804 is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4. This first-in-human study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF299804 in patients ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!